EE156 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure (HF) with Preserved Ejection Fraction (HFPEF) in France, Based on Emperor-Preserved Clinical Trial
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.406
https://www.valueinhealthjournal.com/article/S1098-3015(22)02610-9/fulltext
Title :
EE156 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure (HF) with Preserved Ejection Fraction (HFPEF) in France, Based on Emperor-Preserved Clinical Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02610-9&doi=10.1016/j.jval.2022.09.406
First page :
Section Title :
Open access? :
No
Section Order :
12214